Results 101 to 110 of about 2,004 (157)

Disease-modifying treatments in paroxysmal nocturnal hemoglobinuria: a systematic review of economic evaluations. [PDF]

Cost Eff Resour Alloc
Moradi S, Khajeamiri Y, Zandi S, Keramati M, Mohammadnezhad G.   +4 more
europepmc   +1 more source

Ravulizumab-Cwvz (Ultomiris®)

Oncology Times, 2019
openaire   +2 more sources

Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy. [PDF]

Kidney Med
Aigner C, Prohászka Z, Szilágyi Á, Böhmig GA, Arbeiter K, Schmidt A, Sunder-Plassmann G.   +6 more
europepmc   +1 more source

Ravulizumab in the Management of Refractory Myasthenic Crisis: Clinical and Ventilatory Evidence of Early Recovery-A Case Report. [PDF]

Case Rep Neurol Med
Manlio Sgarzi, Paolo Paone, Paolo Gritti, Emanuela Agazzi, Giorgia Camera, Dario Alimonti.   +5 more
europepmc   +1 more source

Ravulizumab for paroxysmal nocturnal haemoglobinuria

, 2022
openaire   +1 more source

Efficacy and Safety of Crovalimab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta-Analysis. [PDF]

EJHaem
Javaid H, Qadri M, Ali H, Chilaka CF, Syed W, Habib E, Zahin F, Musani A, Khan SA, Rizwan D, Saddique MN, Hajj F.   +11 more
europepmc   +1 more source

Complement Inhibitors in Generalized Myasthenia Gravis: Comparison of Administration Schedules, Efficacy, and Safety. [PDF]

J Clin Med
Di Martino G, Rini N, Bonaventura A, Trovato M, Maccora S, Lima SM, La Seta C, Brighina F, Di Stefano V.   +8 more
europepmc   +1 more source

Patient Preferences for Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatments: Results from a Discrete Choice Experiment Study in the USA. [PDF]

Patient
Abbatemarco JR, Kielhorn A, Yu JC, Fam S, Myers K, Poulos CM, Conway DS.   +6 more
europepmc   +1 more source

Population PK-PD Modeling of Danicopan Add-On Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria Treated With Ravulizumab or Eculizumab. [PDF]

CPT Pharmacometrics Syst Pharmacol
Chen J, Yang F, Li H, Pradhan R, Ortiz S.   +4 more
europepmc   +1 more source

Unmet needs in the care of patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody associated disease: insights from Germany. [PDF]

Neurol Res Pract
Giglhuber K, Bertrand A, Zappe C, Kleiter I, Ayzenberg I, Berthele A, Neuromyelitis Optica Study Group (NEMOS).   +6 more
europepmc   +1 more source